London’s Isomorphic Labs closed a $5 billion Series C round to expand its AI-powered drug discovery platform, while several other British AI firms attracted hundreds of millions for next‑gen chips and defense applications.
London’s Isomorphic Labs announced a landmark $5 billion Series C financing round, positioning the firm at the forefront of AI‑driven drug discovery and signalling a broader surge of capital into UK‑based artificial‑intelligence ventures.
Why Isomorphic Labs’ Funding Matters
The infusion of capital will accelerate the expansion of the company’s proprietary platform, which leverages large‑language models to predict protein structures, optimise molecular design, and shorten the pre‑clinical timeline. Investors cite the firm’s deep ties to Alphabet’s DeepMind and its proven ability to generate viable drug candidates as key differentiators.
Other UK AI Startups Riding the Funding Wave
In the same week, several British AI firms secured sizable rounds for distinct sectors:
- A chip‑design startup raised £200 million to develop energy‑efficient processors for AI workloads.
- A defence‑tech company closed a £150 million series B to embed generative AI into autonomous surveillance systems.
- A biotech AI platform obtained £120 million to scale its predictive analytics for rare‑disease therapeutics.
Implications for the UK Innovation Ecosystem
The clustering of multi‑billion‑dollar investments underscores the UK’s growing reputation as a hub for deep‑tech talent and supportive policy frameworks. Analysts expect the momentum to attract further foreign venture capital, bolster university‑industry collaborations, and stimulate job creation across high‑skill domains.
For readers interested in broader AI developments, the AI category on uxc.news offers continuous coverage of breakthroughs, funding trends, and regulatory updates.
Source: Dwealth News – Top 5 VC deals of the week in AI (Nov 18 2026)